Melanoma is the most dangerous type of skin cancer, largely due to its propensity for recurrence and metastasis, even after removal of malignant tissue. When melanoma reaches advanced stages, the disease becomes refractory to many types of therapy, which has created a need for novel therapeutic strategies to combat the disease. Our group focuses on the oncogenic function of a neuronal receptor, metabotropic glutamate receptor 1 (mGluR1). When mGluR1 is aberrantly expressed in melanocytes, elevated levels of extracellular glutamate mediate the constitutive activation of the receptor to promote cell proliferation. We are exploring the potential synergistic efficacy when combining a glutamatergic signaling inhibitor with a checkpoint inhibitor antibody
Comments: 4 Pages.
[v1] 2017-08-23 06:08:08
Unique-IP document downloads: 17 times
Vixra.org is a pre-print repository rather than a journal. Articles hosted may not yet have been verified by peer-review and should be treated as preliminary. In particular, anything that appears to include financial or legal advice or proposed medical treatments should be treated with due caution. Vixra.org will not be responsible for any consequences of actions that result from any form of use of any documents on this website.
Add your own feedback and questions here:
You are equally welcome to be positive or negative about any paper but please be polite. If you are being critical you must mention at least one specific error, otherwise your comment will be deleted as unhelpful.